Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
A peptide skincare research update highlighted Acetyl Heptapeptide-9 paired with colloidal gold nanoparticle delivery technology — clinical data showed 55% wrinkle reduction within 4 weeks and 20× the collagen-stimulating potency of the free peptide. The case illustrates how 2026's peptide skincare innovation is shifting from new sequence discovery toward advanced delivery vehicles (gold nanoparticles, lipid carriers, microemulsions) that solve the longstanding skin penetration problem for hydrophilic peptides.
A Nature Communications paper introduced a broad-spectrum macrocyclic peptide inhibitor designed for intranasal administration that protects against multiple SARS-CoV-2 Omicron variants in preclinical models. The work expands the macrocyclic peptide modality beyond oncology into respiratory antivirals, where peptide stability and tissue penetration challenges have historically limited clinical translation. Published as Nature Communications article s41467-026-68462-9.
A Nature Communications paper introduced CycloSEL (Cyclic Self-Encoded Libraries), an end-to-end workflow that screens synthetic macrocycle libraries enriched in drug-like 'beyond rule of five' features using affinity selections and tandem mass spectrometry — eliminating the genetic-barcode requirement of traditional macrocyclic peptide discovery. The team validated the approach against the oncology target carbonic anhydrase IX with a 16-million-member library, achieving robust enrichment and accurate identification of true binders. The platform shifts peptide drug discovery toward small molecule-like drug-likeness optimization from day one.
A recent PubMed-indexed study reports that Mu-17 — a novel antimicrobial peptide designed using a bio-inspired approach based on scorpion AMP leucine-zipper-like motifs — showed both antimicrobial and anticancer activity with reduced toxicity. Mu-17 inhibited breast cancer cell proliferation with IC50 of 13 µM and exhibited remarkably low hemolytic activity (18% at 100 µM). The work adds to the emerging category of venom-derived peptides with dual therapeutic applications, complementing ongoing AI-driven antimicrobial peptide discovery efforts disclosed at AACR 2026 and ESCMID 2026.
Lirum Therapeutics announced preclinical data at AACR 2026 demonstrating antitumor activity of LX-101, an IGF-1R–targeted peptide-payload conjugate, in Ewing sarcoma patient-derived xenograft models. As a monotherapy, LX-101 showed meaningful single-agent activity and demonstrated synergy when combined with PI3K or mTOR inhibition. The compound was previously granted FDA "Study May Proceed" authorization for inclusion in the RAPID platform clinical trial for relapsed/refractory Ewing sarcoma and desmoplastic small round cell tumor (DSRCT).
Avacta Therapeutics presented April 21 data at AACR 2026 showing its FAP-enabled peptide-drug conjugate AVA6103, which delivers exatecan via the pre|CISION® platform, achieved a Tumor Selectivity Index three times higher than marketed ADC Enhertu in preclinical models, with tumor Cmax more than one log higher. AVA6103 entered the Phase 1 FOCUS-01 trial (NCT07454642) in March 2026 with initial clinical readout expected later this year.
AlphaGen Therapeutics presented preclinical data at AACR 2026 (April 22) showing its novel macrocyclic peptide-based alpha-emitter radioligand [212Pb]Pb-AG1206 binds fibroblast activation protein with picomolar affinity, achieving rapid tumor accumulation, renal clearance, and a high tumor-to-kidney ratio. A sister candidate [212Pb]Pb-AG1002 targets SSTR2 as a non-agonist alpha therapy for neuroendocrine tumors.
A presentation at the American Academy of Neurology 2026 meeting (closing April 22) reported that in 10,997 chronic migraine patients initiating GLP-1 agonists versus an equal topiramate cohort, GLP-1 users were 10% less likely to visit the ED (23.7% vs 26.4%), 14% less likely to be hospitalized, 42% less likely to start CGRP monoclonal antibodies, and 48% less likely to start valproate over 12 months — adding migraine to the growing list of GLP-1 secondary benefits.
Findings from the Oxford-led BARNARDS II study presented at ESCMID Global 2026 showed WHO-recommended ampicillin plus gentamicin first-line therapy is likely effective for only 1 in 4 neonatal sepsis infections in low- and middle-income countries. Data were collected across 13 tertiary neonatal units in Pakistan, Bangladesh, and Nigeria from February 2024 to October 2025, intensifying the case for AMR-driven peptide alternatives.
Bicycle Therapeutics presented first clinical experiences of a phage-display-derived EphA2-specific bicyclic peptide PET imaging agent in the Diagnostic Biomarkers 2 session at AACR. The imaging agent complements Bicycle's EphA2-targeted therapeutic pipeline (including nuzefatide pevedotin) and could enable patient selection for EphA2-targeted bicyclic peptide drug conjugates across multiple tumor types.
A living systematic review presented at the American Academy of Neurology 2026 Annual Meeting integrating Phase 2/3 trials and real-world data from 2+ million individuals with diabetes found GLP-1 receptor agonist use was associated with a 20-35% lower incidence of dementia versus DPP-4 or SGLT2 inhibitors. Effect was strongest for semaglutide, despite the EVOKE Phase 3 Alzheimer's trial missing its cognitive endpoint.
Novigenix presented first human clinical data at AACR 2026 from its LITOSeek AI-enabled liquid biopsy platform showing dynamic immune-transcriptomic responses in metastatic GEP-NET patients treated with either [212Pb]DOTAMTATE (AlphaMedix) alpha-emitter PRRT or [177Lu]DOTATATE (Lutathera) beta-emitter PRRT. The platform may enable treatment stratification between alpha- and beta-emitter radionuclide therapies.
Nearly half of participants in a Phase 1 trial of BioNTech/Genentech's personalized mRNA neoantigen vaccine autogene cevumeran remain alive up to six years after treatment, with T-cell responses showing no signs of waning. Eight of 16 patients produced durable CD8+ T cells targeting tumor neoantigens after nine doses, with the immune memory still detectable at six-year follow-up. A Phase 2 trial is underway.
University of Nebraska Medical Center's Guangshun Wang lab released APD6, the expanded antimicrobial peptide database, containing 6,309 peptides (3,379 natural AMPs, 2,290 synthetic, 373 AI-predicted) as of January 2026. New features include the Antimicrobial Peptide Information Pipeline (AMPIP) and expanded functional wheel covering anticancer and antidiabetic activity — positioning APD6 as the most comprehensive reference for AMP drug discovery as AI-assisted antibiotic design accelerates.
A Frontiers in Pharmacology review cataloged 176 neuropeptides across 16 families found in the venoms of 107 scorpion species, highlighting Buthus martensii Karsch (BmK) peptides as selective ion channel modulators. Examples include MarTX (selective for BK(α+β4) channels) and BmKTX (Kv1.3 blocker) — positioning scorpion venom as an underexplored source of next-generation neurotherapeutic leads for pain, epilepsy, and autoimmune conditions.
Bicycle Therapeutics delivers an oral presentation (Sunday, April 19, 4:05-4:20 PT) on preclinical activity of BT5528 (nuzefatide pevedotin), its EphA2-targeting bicycle drug conjugate, in cell-line-derived xenograft models of head and neck squamous cell carcinoma. Lukas Stanczuk, Ph.D. leads the presentation under abstract 1325. The HNSCC program complements ongoing Phase 1/2 clinical work combining BT5528 with nivolumab in advanced solid tumors.
Molecular Partners presents three posters at AACR 2026 announcing MP0632 as the first logic-gated Switch-DARPin T-cell engager candidate, targeting MSLN/EpCAM-expressing solid tumors. MP0632 showed tumor regression in dual-antigen preclinical models with limited activity on single-antigen tumors, supporting a favorable therapeutic window. The company also presented updated data for Radio-DARPin MP0712, currently in a US Phase 1/2a trial for DLL3-expressing tumors.
Cogent Biosciences presents preclinical data for its novel pan-KRAS(ON) inhibitor CGT1263 and selective ErbB2 inhibitor CGT4255 at AACR 2026. CGT1263 shows best-in-class cellular potency with a kinase selectivity advantage that could mitigate skin toxicity plaguing multi-RAS inhibitors. CGT4255 is designed with best-in-class CNS penetration to address HER2+ brain metastases, with preclinical synergy data with a HER2 ADC suggesting re-sensitization after ADC resistance.